Immunome (NASDAQ:IMNM) Now Covered by Analysts at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. began coverage on shares of Immunome (NASDAQ:IMNM) in a report issued on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating and a $24.00 price target on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 73.66% from the company’s previous close.

A number of other brokerages have also recently issued reports on IMNM. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Wedbush upped their target price on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. SVB Leerink initiated coverage on Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Guggenheim initiated coverage on Immunome in a research report on Monday, April 15th. They issued a “buy” rating and a $35.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome presently has an average rating of “Buy” and a consensus price target of $30.50.

Immunome Stock Performance

NASDAQ:IMNM opened at $13.82 on Tuesday. The stock has a 50-day simple moving average of $21.76 and a 200-day simple moving average of $15.24. The stock has a market cap of $824.92 million, a P/E ratio of -2.56 and a beta of 1.66. Immunome has a 1 year low of $4.44 and a 1 year high of $30.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. On average, equities research analysts predict that Immunome will post -1.91 EPS for the current year.

Hedge Funds Weigh In On Immunome

A number of large investors have recently modified their holdings of the business. Dorsey Wright & Associates purchased a new position in Immunome in the 3rd quarter valued at approximately $26,000. Jump Financial LLC acquired a new stake in Immunome during the 4th quarter valued at $172,000. Clear Creek Financial Management LLC acquired a new stake in Immunome during the 1st quarter valued at $547,000. Acadian Asset Management LLC acquired a new stake in Immunome during the 3rd quarter valued at $414,000. Finally, Emfo LLC acquired a new stake in shares of Immunome during the fourth quarter worth $633,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.